Clinical Trials · NCT01554618
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 84
- Start date
- Dec 2011
- Locations
- 35 sites, 7 countries
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period)